New trends in immunotherapy to prevent atopic diseases.
Advances in the understanding of the molecular and cellular immunological mechanism of atopy have led to the development of new therapies for allergic diseases. However, only a few new drugs have reached the clinic and none provides long-term immunomodulatory effects. Immunotherapy, through its capacity to produce a long-term, antigen-specific, protective immune response, is the only aetiologic treatment that offers the possibility of preventing or even curing atopic diseases. However, the potential severe side-effects associated with conventional immunotherapy using whole allergen extract limits its widespread use. Thus, novel strategies to minimize the side-effects and improve the efficacy of immunotherapy are of considerable interest in the treatment of atopic diseases. Promising animal and human studies, using approaches such as peptide immunotherapy, DNA vaccination, CpG oligonucleotides and mycobacterial vaccines, suggest that it might be possible to prevent or cure atopic diseases in the future.
Walker
C
C
Novartis Horsham Research Centre, Novartis Pharmaceutical Ltd, Wimblehurst Road, RH12 5AB., West Sussex, UK. christoph.walker@pharma.novartis.com
Zuany-Amorim
C
C
D006801:Humans; D006969:Hypersensitivity, Immediate / Q000517:prevention & control*; D007167:Immunotherapy; D006377:T-Lymphocytes, Helper-Inducer / Q000276:immunology; D014611:Vaccination; D019444:Vaccines, DNA / Q000627:therapeutic use
D019444:Vaccines, DNA